You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Correction: Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis

https://doi.org/10.1136/rmdopen-2024-004480corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To cite: Tanaka Y, Miyazaki Y, Kawanishi M, et al. Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis. RMD Open 2024;10:e004480. doi: 10.1136/rmdopen-2024–0 04 480

    In this article, in the original figure, a study continuation rate for the P/30 group (red line below) is shown as 768.2%, but the correct value is 68.2%. This has now been updated.